Risk of osteoporosis subsequent to chemotherapy for early-stage breast cancer
| Autor: | Christensen, Carina Ørts, Frøslev, T., Cronin Fenton, D., Hermann, P., Ewertz, M. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
musculoskeletal diseases
osteoporosis *chemotherapy *breast cancer *neoplasm *risk human patient osteolysis hip spine adjuvant chemotherapy secondary osteoporosis radius bone density Fisher exact test cohort analysis drug therapy fracture cancer patient forearm absorptiometry X ray imaging cancer chemotherapy prednisolone corticosteroid marker calcium vitamin D musculoskeletal system |
| Zdroj: | Christensen, C Ø, Frøslev, T, Cronin Fenton, D, Hermann, P & Ewertz, M 2015, ' Risk of osteoporosis subsequent to chemotherapy for early-stage breast cancer ', Supportive Care in Cancer, vol. 23, no. SUPPL. 1, 01-03-O, pp. S32-S33 . https://doi.org/10.1007/s00520-015-2712-y |
| DOI: | 10.1007/s00520-015-2712-y |
| Popis: | Introduction: Breast cancer chemotherapy can increase the risk of osteoporosis. Bone loss may be associated with supportive care medication such as cortico-steroids which are the most common cause of secondary osteoporosis with a 7-17 fold increased risk of fractures with daily doses of 10 mg for 3 months. Objectives: We conducted a prospective cohort study to evaluate the effect of adjuvant chemotherapy on bone mineral density (BMD) as a marker of osteoporosis. Methods: Dual-imaging X-ray absorptiometry (DXA) was performed before chemotherapy (baseline) and after completing chemotherapy (4 months later) to measure spine, hip and forearm BMD among 105 breast cancer patients. During standard adjuvant chemotherapy the patients received up to 1425 mg of prednisolone in intervals as required. Patients were advised to take calcium and Vitamin D daily. We correlated the cumulative dose of prednisolone with the percentage change in BMD using Fishers exact tests. Results: Baseline characteristic is shown in table 1. Ten patients were excluded due to osteoporosis at baseline DXA and one due to poor quality scan. None had osteoporosis at the 2nd DXA. Table 2 shows BMD changes from the 94 patients. Median prednisolone dose was 1305 mg with 90 % receiving at least 1100 mg. Overall, cumulative prednisolone dose was not significantly associated with changes in spine, hip and radius BMD (P>0.05). Conclusions: During chemotherapy bone loss by all three DXA measurements was not detected in any patient and no significant association was found to dose of prednisolone. However, we keep following the patients with DXA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|